[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
You seem to have javascript disabled. Please note that many of the page functionalities won't work as expected without javascript enabled.
 
 
Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Journals

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Article Types

Countries / Regions

remove_circle_outline
remove_circle_outline
remove_circle_outline
remove_circle_outline

Search Results (207)

Search Parameters:
Keywords = futility

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
9 pages, 1165 KiB  
Case Report
Should Clinically Assisted Hydration and Nutrition Ever Be Withdrawn for a Neonate with a Chronic Non-Progressive Neurological Condition? A Case Study
by Zhi-Lin Kang, Keson Tay and Poh-Heng Chong
Children 2025, 12(3), 287; https://doi.org/10.3390/children12030287 - 26 Feb 2025
Viewed by 262
Abstract
Background: For infants, withholding or withdrawal of feeding is ethically permissible when the child is imminently dying or chronically and irreversibly comatose. It can also be appropriate in cases of medical futility with a low chance of survival. However, there is much contention [...] Read more.
Background: For infants, withholding or withdrawal of feeding is ethically permissible when the child is imminently dying or chronically and irreversibly comatose. It can also be appropriate in cases of medical futility with a low chance of survival. However, there is much contention in situations where the medical prognosis is uncertain. Case presentation: Annie is a 6-week-old neonate with antenatally acquired cystic encephalomalacia, a chronic non-progressive neurological condition. Her future neurological outcome is uncertain. She is putting on weight in the NICU with stable cardiorespiratory status on room air and tolerates full nasogastric tube feeding but requires frequent oropharyngeal suctioning. Her parents ask to stop tube feeding and allow Annie to die. They deem she has a poor quality of life and is experiencing tremendous suffering. Discussion: Parents’ perceptions of “best interest” and “physical suffering” are explored, alongside those of the healthcare team. Concomitant issues like feeding withdrawal and moral distress are examined in context—that of a newborn where developmental outcomes and disease trajectory are unclear. Conceptual frameworks, empirical evidence and consensus-based ethics guidelines informed a rich and multi-dimensional exposition of a difficult and value-laden decision. Conclusions: While instinctively legitimate, enteral feeding in an infant, in this case with severe neurological impairment, is ultimately still a medical intervention. In contrast to prevailing conventions within adult medicine, the careful and nuanced consideration of benefits and burdens from different stakeholders’ perspectives is critical before any deliberate withdrawal to allow natural death. Full article
(This article belongs to the Section Pediatric Neonatology)
Show Figures

Figure 1

Figure 1
<p>Recommendations for responding to claims of patient suffering.</p>
Full article ">Figure 2
<p>The permissibility of treatment withdrawal from newborn infants based upon predicted future well-being.</p>
Full article ">
16 pages, 3853 KiB  
Article
Diabetes-Mediated STEAP4 Enhances Retinal Oxidative Stress and Impacts the Development of Diabetic Retinopathy
by Brooklyn E. Taylor, Scott J. Howell, Chieh Lee, Zakary Taylor, Katherine Barber and Patricia R. Taylor
Antioxidants 2025, 14(2), 205; https://doi.org/10.3390/antiox14020205 - 11 Feb 2025
Viewed by 303
Abstract
Diabetic retinopathy is the most common diabetic complication of the microvasculature and one of the leading causes of acquired vision loss worldwide. Yet, the current treatments for this blinding disease are futile to many diabetics. Accordingly, new biomarkers and therapeutics for diabetic retinopathy [...] Read more.
Diabetic retinopathy is the most common diabetic complication of the microvasculature and one of the leading causes of acquired vision loss worldwide. Yet, the current treatments for this blinding disease are futile to many diabetics. Accordingly, new biomarkers and therapeutics for diabetic retinopathy are needed. We discovered that STEAP4 (Six-Transmembrane Epithelial Antigen of the Prostate 4) is significantly increased in peripheral blood mononuclear cells of diabetics. STEAP4 expression was gradiently increased from low levels in diabetics without retinopathy to successively higher levels in diabetics with more severe disease. Although the role of STEAP4 in the diabetic retina is unclear, these results provide strong evidence that this metabolic enzyme could be a potential biomarker for diabetic retinopathy progression. Thus, the central goal of this study was to evaluate if this potential biomarker impacts the intrinsic pathologies that lead to the development of diabetic retinopathy. In diabetic mice, STEAP4 was significantly increased and co-localized with 4-Hydroxy-2-nonenal in the Müller glia and photoreceptor layers of the retina. STEAP4 inhibition significantly decreased reactive oxygen species in murine photoreceptor cells, human Müller glia, and retinas of diabetic mice. Administering an intravitreal injection of anti-STEAP4 to diabetic mice halted Occludin degradation in the retinal vasculature. Similarly, anti-STEAP4 treatment of human retina endothelial cells halted cell death mediated by diabetic donor sera. Collectively, our findings provide strong evidence that STEAP4 impacts the intrinsic pathologies that initiate the development of diabetic retinopathy. Suggesting that STEAP4 could be a novel biomarker and clinically relevant therapeutic target for this diabetic complication and blinding disease. Full article
Show Figures

Figure 1

Figure 1
<p><span class="html-italic">STEAP4</span> expression in PBMC of non-diabetic and diabetic patients. Fold increase of <span class="html-italic">STEAP4</span> expression in PBMC (<span class="html-italic">n</span> = 15/group) from non-diabetic patients (grey), diabetics without retinopathy (Diabetic: green), and diabetics with non-proliferative diabetic retinopathy (NPDR: blue) without and with diabetic macular edema (NPDR + DME: red). Fold increases were calculated using 2<sup>−ΔΔCt</sup>, * = <span class="html-italic">p</span> &lt; 0.01 was equated using 1-way nested ANOVA and unpaired student <span class="html-italic">t</span>-test.</p>
Full article ">Figure 2
<p>STEAP4 and iron in the retinas of non-diabetic and diabetic mice. (<b>A</b>) Representative immunoblot of STEAP4 (52 kDa: green) and β-actin (42 kDa: red) of protein lysates, and (<b>B</b>) FIU (fluorescent intensity) quantification of all protein samples (<span class="html-italic">n</span> = 3/group) from non-diabetic (grey) and diabetic (black) mice; 2-months post-diabetes. (<b>C</b>) Representative images of ferritin (green) and DAPI (blue) stained retina cross sections of non-diabetic (ND) and diabetic (DB) mice. (<b>D</b>) Graph of MetaMorph quantification of ferritin fluorescence in all retinas examined (<span class="html-italic">n</span> = 5) of non-diabetic (grey) and diabetic (green) mice; 2-months post diabetes. * = <span class="html-italic">p</span> &lt; 0.01 per ANOVA and <span class="html-italic">t</span>-test.</p>
Full article ">Figure 3
<p>STEAP4 in photoreceptor and Müller glia layers of murine retinas. (<b>A</b>) Images of STEAP4 (green) and DAPI (blue) in 8 μM cross-sections of retinas from non-diabetic and diabetic mice. STEAP4 is outlined by red arrows in the photoreceptor layer and a red box in the Müller glia layers. Levels of STEAP4 fluorescence (FIU) in the total retina (<b>B</b>), photoreceptor layer (<b>C</b>), and retina layers where Müller glia reside (<b>D</b>) of non-diabetic (grey) and diabetic (green) mice (<span class="html-italic">n</span> = 5/group); 2-months post-diabetes. * = <span class="html-italic">p</span> &lt; 0.01 per ANOVA and post-hoc unpaired student <span class="html-italic">t</span>-test.</p>
Full article ">Figure 4
<p>STEAP4 and 4HNE in photoreceptors and Müller glia of diabetic mice. (<b>A</b>) Widefield image of merged (yellow) STEAP4 (green) and 4HNE (red) in a retinal cross section from a diabetic mouse. (<b>B</b>) Representative confocal images of the photoreceptor outer segment, displaying STEAP4 (green) and 4HNE (red) colocalization (yellow). (<b>C</b>) Confocal images of STEAP4 (green) colocalized (yellow) in Vimentin (red) stained Müller glia. (<b>D</b>) Confocal images of 4HNE (green) colocalization (yellow) with Vimentin (red) stained Müller glia. All images are representative of retina cross-sections from diabetic mice analyzed (<span class="html-italic">n</span> = 5) 2-months after diabetic conditions were confirmed.</p>
Full article ">Figure 5
<p>ROS production in anti-STEAP4 treated photoreceptors and Müller glia. Müller glia (<b>A</b>) (<span class="html-italic">n</span> = 6) and (<b>B</b>) 661 W photoreceptor-like cone cells (<span class="html-italic">n</span> = 6) were incubated in euglycemic conditioned media containing 5 mM of glucose (white) or hyperglycemic conditioned media containing 25 mM of glucose without (grey) or with: 1 μg (blue), 2 μg (red), or 5 μg (black) of anti-STEAP4 for 18 h. Human Müller glia (<b>A</b>) and mouse 661 W cells (<b>B</b>) were collected and incubated with H<sub>2</sub>DCFDA (ROS indicator) for flow cytometry quantification of ROS (H<sub>2</sub>DCFDA fluorescence (RLU × 10<sup>3</sup>)). * = <span class="html-italic">p</span> &lt; 0.01, which was equated by 2-way ANOVA and Tukey’s post-hoc unpaired student <span class="html-italic">t</span>-test.</p>
Full article ">Figure 6
<p>ROS in anti-STEAP4 treated murine retinas. (<b>A</b>) Representative histogram overlay from flow cytometry analysis of H<sub>2</sub>DCFDA<sup>+</sup> (ROS producing) retina cells from untreated non-diabetic (black: with a peak value of 412), anti-STEAP4 treated non-diabetic (red), untreated diabetic (grey: with a peak value of 3188), diabetic KLH control (blue), and anti-STEAP4 treated diabetic (green) C57BL/6 mice; 2-months post-diabetes. (<b>B</b>) Quantification of H<sub>2</sub>DCFDA<sup>+</sup> (ROS producing) retina cells in all samples (<span class="html-italic">n</span> = 5/group) analyzed by flow cytometry; <span class="html-italic">p</span>-values were equated using 2-way ANOVA and Tukey’s post-hoc unpaired student <span class="html-italic">t</span>-tests.</p>
Full article ">Figure 7
<p>Levels of Occludin in lysates from murine retinal vasculature. (<b>A</b>) Representative WES gel of Occludin (65 kDa: red) and β-actin (42 kDa: blue). Representative electropherograms of β-actin (<b>B</b>) and Occludin (<b>C</b>) of protein lysates from retinal vasculature of untreated (DB CTRL: blue) and anti-STEAP4 treated (αSTEAP: red) diabetic mice. (<b>D</b>) Levels of Occludin in all protein lysate samples (<span class="html-italic">n</span> = 5/group) analyzed from untreated (blue) and anti-STEAP4 treated (red) diabetic mice; 2-months post-diabetes. * = <span class="html-italic">p</span> &lt; 0.01; per 2-way ANOVA and post-hoc unpaired student <span class="html-italic">t</span>-test.</p>
Full article ">Figure 8
<p>Human retina endothelial cell death in cells cultured with patient sera. Untreated (black) or anti-STEAP4 treated (red) hREC (1 × 10<sup>6</sup>) were cultured with sera of non-diabetics (ND) or sera of patients with NPDR and diabetic macular edema (DME) for 18 h. Cells were collected and incubated with 7-AAD for flow cytometry analysis of hREC cell death (<span class="html-italic">n</span> = 15/group). The <span class="html-italic">p</span>-value was calculated using 2-way ANOVA analysis and Tukey’s post-hoc unpaired student <span class="html-italic">t</span>-tests.</p>
Full article ">
12 pages, 2338 KiB  
Review
Updates in Biliary Atresia: Aetiology, Diagnosis and Surgery
by Mark Davenport
Children 2025, 12(1), 95; https://doi.org/10.3390/children12010095 - 16 Jan 2025
Viewed by 889
Abstract
Biliary atresia (BA) is an obliterative disease of the bile ducts affecting between 1 in 10,000–20,000 infants with a predominance in Asian countries. It is clinically heterogeneous with a number of distinct variants (e.g., isolated, Biliary Atresia Splenic Malformation syndrome, Cat-eye syndrome, cystic [...] Read more.
Biliary atresia (BA) is an obliterative disease of the bile ducts affecting between 1 in 10,000–20,000 infants with a predominance in Asian countries. It is clinically heterogeneous with a number of distinct variants (e.g., isolated, Biliary Atresia Splenic Malformation syndrome, Cat-eye syndrome, cystic BA, and CMV-associated BA). Facts about its aetiology are hard to encounter but might include genetic, developmental, exposure to an environmental toxin, or perinatal virus infection. However, the cholestatic injury triggers an intrahepatic fibrotic process beginning at birth and culminating in cirrhosis some months later. Affected infants present with a triad of conjugated jaundice, pale stools, and dark urine and may have hepatosplenomegaly upon examination, with later ascites coincident with the onset of progressive liver disease. Rapid, efficient, and expeditious diagnosis is essential with the initial treatment being surgical, typically with an attempt to restore the bile flow (Kasai portoenterostomy (KPE)) or primary liver transplantation (<5%) if considered futile. Failure to restore bile drainage or the onset of complications such as recurrent cholangitis, treatment-resistant varices, ascites, hepatopulmonary syndrome, and occasionally malignant change are usually managed by secondary liver transplantation. This issue summarises recent advances in the disease and points a way to future improvements in its treatment. Full article
(This article belongs to the Special Issue Pediatric Digestive Tract Disease: Surgical Aspects)
Show Figures

Figure 1

Figure 1
<p><b>Working hypothesis on the aetiological mechanisms underlying biliary atresia</b>. This implies that BA is a final common pathway with various independent mechanism—such as viral infection (±aberrant immune response), developmental derangement (±genetic mutation), ischaemic injury, environmental toxins etc.).</p>
Full article ">Figure 2
<p><b>Aetiological Heterogeneity: Cystic biliary atresia</b> with cholangiogram (part <b>A</b>) showing contrast retention in the cyst, absence of flow into the intestine, and abnormally fine, interconnecting etiolated intrahepatic bile ducts. <b>Biliary atresia splenic malformation syndrome</b> showing a pre-duodenal portal vein (part <b>B</b>, arrow) and left-sided polysplenia (part <b>C</b>, circled). <b>Isolated biliary atresia</b> (part <b>D</b>) showing (a) mobilized atrophic gallbladder, (b) umbilical vein and (c) sling around right hepatic artery. Cut surface of the porta hepatis before Roux loop reconstruction (part <b>E</b>). Photomicrograph of cut surface showing scattered biliary ductules within a fibroinflammatory stroma (vimentin-positive) (part <b>F</b>). Reprinted with permission from Ref. [<a href="#B5-children-12-00095" class="html-bibr">5</a>]. Copyright 2024 Springer Nature.</p>
Full article ">Figure 3
<p>The centralisation effect: comparison between the biliary atresia management in England and Wales and Germany. [Background maps courtesy of <a href="https://alearningfamily.com/" target="_blank">https://alearningfamily.com/</a>, accessed on 1 December 2024].</p>
Full article ">
9 pages, 524 KiB  
Article
Impact of Echocardiographic Cardiac Damage Staging on Mortality and Heart Failure Hospitalizations in Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Replacement
by José A. Parada-Barcia, Manuel Barreiro-Pérez, José Antonio Baz, Rodrigo Estévez-Loureiro, Julio César Echarte, Victor Jiménez-Díaz and Andrés Íñiguez-Romo
J. Clin. Med. 2025, 14(2), 408; https://doi.org/10.3390/jcm14020408 - 10 Jan 2025
Viewed by 548
Abstract
Background: A significant proportion of elderly patients referred to transcatheter aortic valve replacement (TAVR) do not experience an improvement of their symptoms. New tools are needed to better select candidates and avoid futile procedures. The objective of this study was to evaluate the [...] Read more.
Background: A significant proportion of elderly patients referred to transcatheter aortic valve replacement (TAVR) do not experience an improvement of their symptoms. New tools are needed to better select candidates and avoid futile procedures. The objective of this study was to evaluate the impact of a new echocardiographic classification which assesses the consequences of chronic elevation of afterload on mortality and hospitalizations for heart failure (HF) in patients with severe AS undergoing TAVR. Methods: This study included 130 high-risk, elderly patients with severe AS who underwent TAVR between January 2018 and December 2019. The patients were classified into three groups according to anatomical and functional features based on transthoracic echocardiography (TTE). The combined end point was death from all causes and HF admissions. Results: Echocardiographic staging was significantly associated with increased rates of death and HF hospitalizations. After multivariate adjustment, the patients with severe cardiac damage exhibited a significant increase in hospitalizations for HF and all-cause mortality (HR 4.79; 95% CI 2.00–11.05; p = 0.000), whereas the moderate cardiac damage group did not (HR 1.84; 95% CI 0.88–3.84; p = 0.104). Conclusions: Echocardiographic staging of severe AS could be a useful tool for predicting HF hospitalizations and all-cause mortality after TAVR in elderly, high-risk patients. Evaluating cardiac damage with this new score may be a promising strategy to better select patients and improve outcomes following TAVR. Full article
(This article belongs to the Special Issue Global Expert Views on Aortic Valve Repair and Replacement)
Show Figures

Figure 1

Figure 1
<p>Incidence of all-cause mortality and hospitalizations for heart failure according to the echocardiographic cardiac damage stage.</p>
Full article ">
11 pages, 235 KiB  
Opinion
Exploring the Need to Use “Plagiarism” Detection Software Rationally
by Petar Milovanovic, Tatjana Pekmezovic and Marija Djuric
Publications 2025, 13(1), 1; https://doi.org/10.3390/publications13010001 - 2 Jan 2025
Viewed by 1031
Abstract
Universities and journals increasingly rely on software tools for detecting textual overlap of a scientific text with the previously published literature to detect potential plagiarism. Although software outputs need to be carefully reviewed by competent humans to verify the existence of plagiarism, university [...] Read more.
Universities and journals increasingly rely on software tools for detecting textual overlap of a scientific text with the previously published literature to detect potential plagiarism. Although software outputs need to be carefully reviewed by competent humans to verify the existence of plagiarism, university and journal staff, for various reasons, often erroneously interpret the degree of plagiarism based on the percentage of textual overlap shown in the similarity report. This is often accompanied by explicit recommendations to the author(s) to paraphrase the text to achieve an “acceptable” percentage of overlap. Here, based on the available literature and real-world examples from similarity reports, we provide a classification with extensive examples of phrases that falsely inflate the similarity index and argue the futility and dangers of rephrasing such statements just for the sake of reducing the similarity index. The examples provided in this paper call for a more reasonable assessment of text similarity. To fully endorse the principles of academic integrity and prevent loss of clarity of the scientific literature, we believe it is important to shift from pure bureaucratic and quantificational view on the originality of scientific texts to human-centered qualitative assessment of the manuscripts, including the software outputs. Full article
11 pages, 1854 KiB  
Article
Long-Term Outcome of Elderly Patients with Severe Aortic Stenosis Undergoing a Tailored Interventional Treatment Using Frailty-Based Management: Beyond the Five-Year Horizon
by Augusto Esposito, Ilenia Foffa, Paola Quadrelli, Luca Bastiani, Cecilia Vecoli, Serena Del Turco, Sergio Berti and Annamaria Mazzone
J. Pers. Med. 2024, 14(12), 1164; https://doi.org/10.3390/jpm14121164 - 21 Dec 2024
Viewed by 905
Abstract
Background: Elderly patients with severe aortic stenosis (AS) need individualized decision-making in their management in order to benefit in terms of survival and improvement of quality of life. Frailty, a common condition in elderly patients, needs to be considered when weighing treatment options. [...] Read more.
Background: Elderly patients with severe aortic stenosis (AS) need individualized decision-making in their management in order to benefit in terms of survival and improvement of quality of life. Frailty, a common condition in elderly patients, needs to be considered when weighing treatment options. Aim: We aimed to evaluate outcomes including survival and functional parameters according to disability criteria at six years of follow-up in an older population treated for severe AS using a frailty-based management. Methods: We evaluated data derived from a pilot clinical project involving elderly patients with severe AS referred to a tailored management based on classification by Fried’s score into pre-frail, early frail, and frail and a multidimensional geriatric assessment. A Frailty, Inflammation, Malnutrition, and Sarcopenia (FIMS) score was used to predict the risk of mortality at six years of follow-up. Functional status was evaluated by telephonic interview. Results: At six years of follow-up, we found a survival rate of 40%. It was higher in the pre-frail patients (long rank < 0.001) and in the patients who underwent TAVR treatment (long rank < 0.001). The cut-off FIMS score value of ≥1.28 was an independent determinant associated with a higher risk of mortality at six years of follow-up (HR 2.91; CI 95% 1.7–5.1; p-value 0.001). We found a moderate increase of disability levels, malnutrition status, comorbidities, and number of drugs, but none of them self-reported advanced NYHA class III–IV heart failure. Conclusion: An accurate clinical–instrumental and functional geriatric evaluation in an elderly population with AS is required for a non-futile interventional treatment in terms of survival and functional status even in long-term follow-up. Full article
(This article belongs to the Special Issue Geriatric Medicine: Towards Personalized Medicine)
Show Figures

Figure 1

Figure 1
<p>Geriatric functional assessment at follow-up compared to basal evaluation, related to the type of intervention (surgical aortic valve replacement/transcatheter aortic valve replacement and balloon aortic valve).</p>
Full article ">Figure 2
<p>Kaplan–Meier survival curves. The survival rate at 6 years was higher in pre-frail patients, long rank &lt; 0.0001).</p>
Full article ">Figure 3
<p>Kaplan–Meier survival curves. The survival rate at 6 years was higher in the patients who underwent TAVR treatment, long rank &lt; 0.0001). SAVR: surgical aortic valve replacement; TAVR: transcatheter aortic valve replacement; BAV: balloon aortic valve; MT: medical therapy.</p>
Full article ">Figure 4
<p>A graphic representation of the present and future strategies for tailored, appropriate management of aortic stenosis in elderly patients.</p>
Full article ">
17 pages, 2166 KiB  
Article
Immunogenic Cell Death Traits Emitted from Chronic Lymphocytic Leukemia Cells Following Treatment with a Novel Anti-Cancer Agent, SpiD3
by Elizabeth Schmitz, Abigail Ridout, Audrey L. Smith, Alexandria P. Eiken, Sydney A. Skupa, Erin M. Drengler, Sarbjit Singh, Sandeep Rana, Amarnath Natarajan and Dalia El-Gamal
Biomedicines 2024, 12(12), 2857; https://doi.org/10.3390/biomedicines12122857 - 16 Dec 2024
Viewed by 1177
Abstract
Background: Targeted therapies (e.g., ibrutinib) have markedly improved chronic lymphocytic leukemia (CLL) management; however, ~20% of patients experience disease relapse, suggesting the inadequate depth and durability of these front-line strategies. Moreover, immunotherapeutic success in CLL has been stifled by its pro-tumor microenvironment milieu [...] Read more.
Background: Targeted therapies (e.g., ibrutinib) have markedly improved chronic lymphocytic leukemia (CLL) management; however, ~20% of patients experience disease relapse, suggesting the inadequate depth and durability of these front-line strategies. Moreover, immunotherapeutic success in CLL has been stifled by its pro-tumor microenvironment milieu and low mutational burden, cultivating poor antigenicity and limited ability to generate anti-tumor immunity through adaptive immune cell engagement. Previously, we have demonstrated how a three-carbon-linker spirocyclic dimer (SpiD3) promotes futile activation of the unfolded protein response (UPR) in CLL cells through immense misfolded-protein mimicry, culminating in insurmountable ER stress and programmed CLL cell death. Method: Herein, we used flow cytometry and cell-based assays to capture the kinetics and magnitude of SpiD3-induced damage-associated molecular patterns (DAMPs) in CLL cell lines and primary samples. Result: SpiD3 treatment, in vitro and in vivo, demonstrated the capacity to propagate immunogenic cell death through emissions of classically immunogenic DAMPs (CALR, ATP, HMGB1) and establish a chemotactic gradient for bone marrow-derived dendritic cells. Conclusions: Thus, this study supports future investigation into the relationship between novel therapeutics, manners of cancer cell death, and their contributions to adaptive immune cell engagement as a means for improving anti-cancer therapy in CLL. Full article
Show Figures

Figure 1

Figure 1
<p>CLL cells display ecto-CALR following SpiD3 treatment. HG-3 ((<b>A</b>,<b>B</b>); n = 3); OSU-CLL ((<b>C</b>,<b>D</b>); n = 3); or patient-derived CLL ((<b>E</b>,<b>F</b>); n = 5) cells were treated with vehicle (Veh), SpiD3 (0.25–2 µM), FeCl<sub>2</sub> (160 μM), or the positive control, etoposide (Etop; 20 µM) for the indicated durations. Viable cells were analyzed by flow cytometry for changes in surface CALR expression (ecto-CALR). Primary patient-derived CLL cells were additionally designated as CD19+/CD5+ by flow cytometry. Data are presented as mean ± SEM. Comparisons across treatment groups were analyzed with respect to the vehicle by one-way ANOVA. Asterisks denote magnitude of significance: * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001, **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 2
<p>SpiD3 treatment evokes extracellular ATP release. HG-3 (<b>A</b>); and OSU-CLL (<b>B</b>) cells were treated over 24 h (n = 3) with vehicle (Veh), SpiD3 (0.5–2 µM), or the positive control, etoposide (Etop; 20 µM). Extracellular ATP measurements at 8, 16, and 24 h were parsed out to evaluate the average extracellular ATP measured at these timepoints in comparison to the matched timepoint vehicle. Data are presented as mean ± SEM. Comparisons across treatment groups were analyzed with respect to the matched timepoint average vehicle by one-way ANOVA. Asterisks denote magnitude of significance: * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 3
<p>SpiD3-treated cells release extracellular HMGB1. Supernatant from HG-3 ((<b>A</b>,<b>B</b>); n = 3); OSU-CLL ((<b>C</b>,<b>D</b>); n = 3); and primary CLL ((<b>E</b>); n = 10) cells were evaluated for extracellular HMGB1 after 24 h or 48 h of treatment with the vehicle (Veh), SpiD3 (0.5–2 µM), ibrutinib (1 µM), or positive control, etoposide (Etop; 20 µM). Data are presented as mean ± SEM. Comparisons across treatment groups were analyzed with respect to the vehicle by one-way ANOVA. Asterisks denote magnitude of significance: * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001, **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 4
<p>Chemotactic potential of SpiD3-treated cell supernatants. Bone marrow dendritic cells (BMDCs) were allowed to migrate for 6 h toward supernatant collected from HG-3 (<b>A</b>); and OSU-CLL (<b>B</b>) cells after 24 h treatment with the vehicle (Veh), SpiD3 (0.5–2 µM), or the positive control, etoposide (Etop; 20 µM). GM-CSF (20 ng/mL) stimulated media, and supernatant derived from heat-shocked CLL cells (HS) served as positive chemotactic controls. The number of migrated BMDCs were counted via flow cytometry analysis (n = 3). The chemotactic index is a comparison of the migrated events observed from treatment conditions to that of the vehicle condition. Data are represented as mean ± SEM. Comparisons across treatment groups were analyzed with respect to the vehicle by one-way ANOVA. Asterisks denote magnitude of significance: * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01, *** <span class="html-italic">p</span> &lt; 0.001, **** <span class="html-italic">p</span> &lt; 0.0001.</p>
Full article ">Figure 5
<p><span class="html-italic">In vivo</span> SpiD3 treatment yields an immunostimulatory response. (<b>A</b>) Schematic of experiment design: Eµ-TCL1 mice with comparable leukemia burden were treated intravenously with SpiD3 prodrug (SpiD3_AP, 10 mg/kg; n = 6) or equivalent vehicle (Veh; 50% PEG400, 10% DMSO, 40% water; n = 5) once daily for 3 days, as previously reported [<a href="#B20-biomedicines-12-02857" class="html-bibr">20</a>]. Following treatment, spleen cells were collected for flow cytometry analysis and plasma was isolated from murine blood; (<b>B</b>) leukemic (CD19+/CD5+) cells from murine spleens were analyzed by flow cytometry for changes in surface CALR expression (ecto-CALR) and compared to the percentage of leukemic cells detected in spleens of the same mice (as reported in Eiken, et al. [<a href="#B20-biomedicines-12-02857" class="html-bibr">20</a>]). The concentrations of plasma inflammatory cytokines and chemokines were assessed using Mouse Anti-Virus Response (<b>C</b>,<b>E</b>); and Mouse Pro-Inflammatory Chemokine (<b>D</b>,<b>F</b>) LEGENDplex™ flow cytometry-based multiplex immunoassays. (<b>C</b>,<b>D</b>) Heatmaps display fold change in the plasma analyte concentration compared to the average of vehicle-treated mice. Columns represent individual mice per treatment group. (<b>E</b>,<b>F</b>) Raw plasma analyte concentration and correlation with the percentage of CD19+/CD5+ spleen-derived cells are shown for select analytes. Individual data points (Veh = black circles; SpiD3_AP = blue triangles) in addition to summary statistics (mean ± SEM) are shown. Comparisons between treatment groups were analyzed by unpaired <span class="html-italic">t</span>-test. Asterisks denote magnitude of significance: * <span class="html-italic">p</span> &lt; 0.05, ** <span class="html-italic">p</span> &lt; 0.01.</p>
Full article ">Figure 6
<p>Illustrative summary of SpiD3 anti-leukemic activity. CLL cell cytotoxicity via SpiD3 is demonstrated by: (i) inhibition of NF-κB signaling; and (ii) accumulation of unfolded proteins, promoting ER stress, activating a futile UPR and, subsequently, the associated programmed cell death pathways. ER stress is a proposed prerequisite for immunogenic DAMP emissions; we hypothesize it is this facet of SpiD3-associated effects that result in detectable hallmarks of immunogenic cell death from CLL cells. This diagram is adapted from Eiken, et al. CLL, chronic lymphocytic leukemia; DC, dendritic cell; iDAMP, immunogenic damage-associated molecular pattern; ER, endoplasmic reticulum; UPR, unfolded protein response.</p>
Full article ">
21 pages, 9220 KiB  
Review
Structural and Functional Integration of Tissue-Nonspecific Alkaline Phosphatase Within the Alkaline Phosphatase Superfamily: Evolutionary Insights and Functional Implications
by Iliass Imam, Gilles Jean Philippe Rautureau, Sébastien Violot, Eva Drevet Mulard, David Magne and Lionel Ballut
Metabolites 2024, 14(12), 659; https://doi.org/10.3390/metabo14120659 - 25 Nov 2024
Viewed by 930
Abstract
Phosphatases are enzymes that catalyze the hydrolysis of phosphate esters. They play critical roles in diverse biological processes such as extracellular nucleotide homeostasis, transport of molecules across membranes, intracellular signaling pathways, or vertebrate mineralization. Among them, tissue-nonspecific alkaline phosphatase (TNAP) is today increasingly [...] Read more.
Phosphatases are enzymes that catalyze the hydrolysis of phosphate esters. They play critical roles in diverse biological processes such as extracellular nucleotide homeostasis, transport of molecules across membranes, intracellular signaling pathways, or vertebrate mineralization. Among them, tissue-nonspecific alkaline phosphatase (TNAP) is today increasingly studied, due to its ubiquitous expression and its ability to dephosphorylate a very broad range of substrates and participate in several different biological functions. For instance, TNAP hydrolyzes inorganic pyrophosphate (PPi) to allow skeletal and dental mineralization. Additionally, TNAP hydrolyzes pyridoxal phosphate to allow cellular pyridoxal uptake, and stimulate vitamin B6-dependent reactions. Furthermore, TNAP has been identified as a key enzyme in non-shivering adaptive thermogenesis, by dephosphorylating phosphocreatine in the mitochondrial creatine futile cycle. This latter recent discovery and others suggest that the list of substrates and functions of TNAP may be much longer than previously thought. In the present review, we sought to examine TNAP within the alkaline phosphatase (AP) superfamily, comparing its sequence, structure, and evolutionary trajectory. The AP superfamily, characterized by a conserved central folding motif of a mixed beta-sheet flanked by alpha-helices, includes six subfamilies: AP, arylsulfatases (ARS), ectonucleotide pyrophosphatases/phosphodiesterases (ENPP), phosphoglycerate mutases (PGM), phosphonoacetate hydrolases, and phosphopentomutases. Interestingly, TNAP and several ENPP family members appear to participate in the same metabolic pathways and functions. For instance, extra-skeletal mineralization in vertebrates is inhibited by ENPP1-mediated ATP hydrolysis into the mineralization inhibitor PPi, which is hydrolyzed by TNAP expressed in the skeleton. Better understanding how TNAP and other AP family members differ structurally will be very useful to clarify their complementary functions. Structurally, TNAP shares the conserved catalytic core with other AP superfamily members but has unique features affecting substrate specificity and activity. The review also aims to highlight the importance of oligomerization in enzyme stability and function, and the role of conserved metal ion coordination, particularly magnesium, in APs. By exploring the structural and functional diversity within the AP superfamily, and discussing to which extent its members exert redundant, complementary, or specific functions, this review illuminates the evolutionary pressures shaping these enzymes and their broad physiological roles, offering insights into TNAP’s multifunctionality and its implications for health and disease. Full article
(This article belongs to the Section Cell Metabolism)
Show Figures

Figure 1

Figure 1
<p>Topology of representative members of the AP superfamily. (<b>A</b>) Human TNAP, (<b>B</b>) human ENPP5, (<b>C</b>) human ARSA, (<b>D</b>) human ARSB, (<b>E</b>) human ARSK, (<b>F</b>) human SULF1, (<b>G</b>) human ENPP1. The central core is conserved in members of the AP, ENPP, and ARS families, with a minimal conservation of 7 to 8 beta strands and 6 to 7 alpha helices highlighted in solid red lines. The additional domains of ENPP1, somatomedin at the N-terminus (1–192), and non-specific DNA/RNA endonuclease at the C-terminus (637–925) are not shown for clarity. The secondary structures, alpha helices, and beta strands are shown in yellow and blue, respectively. The catalytic residues are indicated by the letters S (serine), T (threonine), and C (cysteine).</p>
Full article ">Figure 2
<p>Conservation of the core in the AP superfamily. (<b>A</b>) Examples of domain organization in various members of the superfamily. (<b>B</b>) Superposition of 7 representative members of the superfamily, including AP, ENPP, and ARS. The members are TNAP (ALPL) in pink (PDB code: 7YIV), ENPP1 in orange (PDB code: 6WEW), ENPP5 in red (PDB code: 5VEM), ARSA in light blue (PDB code: 1AUK), ARSB in yellow (PDB code: 1FSU), ARSK in dark blue (AlphaFold model), and SULF1 in light green (AlphaFold model). The superposition focuses solely on the central core, highlighting the extreme organizational variability and the lack of overall folding conservation outside the catalytic core. (<b>C</b>) Extraction of the minimal secondary structures from the previous superposition that constitutes the central core. This reveals the high conservation of the central core’s folding, with its 7 to 8 beta strands and 6 to 7 alpha helices. The star marks the position of the nucleophilic catalytic residue: serine for TNAP, threonine for ENPP1 and ENPP5, modified cysteine for ARSA (formylglycine) and ARSB (sulfate ester), and cysteine for the AlphaFold models of ARSK and SULF1. (<b>D</b>) Conserved positioning of the catalytic residue at the end of the helix.</p>
Full article ">Figure 3
<p>Comparison of dimeric organization in AP and ENPP. (<b>A</b>–<b>F</b>) Examples of characteristic dimers of AP and ENPP. (<b>G</b>–<b>L</b>) Organization of the central β-sheet characteristic of the AP family. The Van der Waals surface of the dimer is shown in transparency. The dimeric organization is consistent across the AP family, including human enzymes like TNAP (PDB code: 7YIV) (panels <b>A</b>,<b>G</b>) and PLAP (PDB code: 1ZED) (panels <b>B</b>,<b>H</b>), as well as the <span class="html-italic">E. coli</span> AP enzyme (panels <b>C</b>,<b>E</b>). This organization features conserved central β-sheets, typical of the AP fold, facing each other without complementary interactions (panels <b>G</b>,<b>H</b>,<b>E</b>). A similar AP-like interface is observed in some ENPP family members, particularly in murine ENPP6 (panel <b>D</b>) (PDB code: 5EGH). An AlphaFold model of the human ENPP6 dimer suggests a similar organization (panel <b>F</b>) (PDB code: 5VEN). The same AP-like interface is observed in murine ENPP5, with the conserved central β-sheets facing each other with a slight offset and no complementary interactions (panels <b>J</b>,<b>K</b>,<b>L</b>).</p>
Full article ">Figure 4
<p>Evolution of members of the AP superfamily: (<b>A</b>) Phylogenetic tree of the AP superfamily members. Multiple sequence alignment of all human members of the AP superfamily was performed with the MAFFT program version 7 [<a href="#B54-metabolites-14-00659" class="html-bibr">54</a>]. The sequences used were retrieved from the UniProtKB database, with the corresponding UniProt codes listed next to the enzyme names. Conserved blocks were selected by using BMGE1.12 [<a href="#B55-metabolites-14-00659" class="html-bibr">55</a>] and the BLOSUM30 [<a href="#B56-metabolites-14-00659" class="html-bibr">56</a>] matrix. Two hundred sites were kept for further analysis after character trimming was performed by BMGE [<a href="#B55-metabolites-14-00659" class="html-bibr">55</a>]. Phylogenetic analyses were performed, with the LG model and a gamma correction, using a bootstrapped maximum-likelihood approach with PhyML 3.0 [<a href="#B57-metabolites-14-00659" class="html-bibr">57</a>]. The phylogenetic tree was generated and visualized with iTOL software Version 6.9.1 [<a href="#B58-metabolites-14-00659" class="html-bibr">58</a>]. (<b>B</b>,<b>D</b>,<b>F</b>) Examples of characteristic dimers observed in ARS. (<b>C</b>,<b>E</b>,<b>G</b>) Central β-sheet illustrating the diversity of organization in ARS. The Van der Waals surface of the dimer is shown in transparency. Two types of organization are presented here: one corresponding to GALNS (PDB code: 4FDJ) and ARSA (PDB code: 1AUK) (<b>B</b>–<b>E</b>) and the other to N-sulphoglucosamine sulphohydrolase (SGSH; PDB code: 4MHX) (<b>F</b>,<b>G</b>).</p>
Full article ">Figure 5
<p>Comparison of the catalytic centers of AP, ENPP, and ARS, representative of each family. (<b>A</b>) Catalytic center of ARSC (PDB code: 8EG3). Conserved residues of the family are indicated. Calcium is shown as a green sphere. (<b>B</b>) Catalytic center of ENPP1 (PDB code: 6WEU). Conserved residues of the family are indicated. Zinc 1 and 2 are shown as orange spheres. (<b>C</b>) Catalytic center of TNAP (PDB code: 7YIV). Conserved residues of the family are indicated. Zinc 1 and 2 are shown as pink spheres, and magnesium is shown as a green sphere. (<b>D</b>) Superposition of representative members from the AP and ENPP families. Conserved residues between the two families are shown, indicating that the catalytic residue and the residues interacting with zinc are almost perfectly superimposable. The residues of TNAP and ENPP1 are numbered. The structures used in the comparison are TNAP in purple (PDB code: 7YIV), PLAP in light green (PDB code: 1ZED), ENPP1 in orange (PDB code: 6WEU), ENPP2 in yellow (PDB code: 5M7M), ENPP3 in light blue (PDB code: 6C02), ENPP4 in cyan (PDB code: 4LQY), ENPP5 in red (PDB code: 5VEM), and ENPP7 in dark green (PDB code: 5UDY). (<b>E</b>–<b>H</b>) Characteristic crevice of ARS with the catalytic pocket at its bottom. (<b>E</b>,<b>F</b>) Electrostatic surfaces of GALNS (PDB code: 4FDJ) and IDS (PDB code: 5FQL) reveal a highly positively charged crevice. A citrate molecule is visible at the bottom of the GALNS structure. (<b>G</b>,<b>H</b>) Electrostatic and hydrophobic surfaces of the binding site of ARSC (PDB code: 8EG3), showing one side that is positively charged (blue) (<b>G</b>) and the other side that is hydrophobic (yellow) (<b>H</b>). (<b>I</b>–<b>K</b>) Electrostatic surfaces of ENPP1, PLAP, and TNAP, with all three enzymes similarly oriented. Zn<sup>2+</sup> ions are indicated by red and gray spheres. In ENPP1, adenosine-5′-thio-monophosphate is visible in the active site, with the base positioned in the nucleotide-binding slot stabilized by residues Y340 and F257 (<b>I</b>). In PLAP and TNAP, the magnesium-binding helix occupies the nucleotide-binding slot present in ENPP1, necessitating a different substrate accommodation. This is observed in PLAP (<b>J</b>) with the presence of PNP. The gatekeeper residues, D428 and E429 for PLAP and R450 and H451 for TNAP, are shown as sticks (<b>J</b>,<b>K</b>).</p>
Full article ">
17 pages, 2434 KiB  
Article
A Fuzzy AHP and PCA Approach to the Role of Media in Improving Education and the Labor Market in the 21st Century
by Branislav Sančanin, Aleksandra Penjišević, Dušan J. Simjanović, Branislav M. Ranđelović, Nenad O. Vesić and Maja Mladenović
Mathematics 2024, 12(22), 3616; https://doi.org/10.3390/math12223616 - 19 Nov 2024
Cited by 1 | Viewed by 817
Abstract
In a hyperproductive interactive environment, where speed and cost-effectiveness often overshadow accuracy, the media’s role is increasingly shifting towards an educational function, beyond its traditional informative and entertaining roles. This shift, particularly through the promotion of science and education, aims to bridge the [...] Read more.
In a hyperproductive interactive environment, where speed and cost-effectiveness often overshadow accuracy, the media’s role is increasingly shifting towards an educational function, beyond its traditional informative and entertaining roles. This shift, particularly through the promotion of science and education, aims to bridge the gap between educational institutions and the labor market. In this context, the importance of 21st-century competencies—encompassing a broad range of knowledge and skills—becomes increasingly clear. Educational institutions are now expected to equip students with relevant, universally applicable, and market-competitive competencies. This paper proposes using a combination of principal component analysis (PCA) and fuzzy analytic hierarchy process (FAHP) to rank 21st-century competencies developed throughout the educational process to improve the system. The highest-ranked competency identified is the ability to manage information—specifically, gathering and analyzing information from diverse sources. It has been shown that respondents who developed “soft skills” and media literacy during their studies are better able to critically assess content on social networks and distinguish between credible and false information. The significance of this work lies in its focus on the damaged credibility of online media caused by user-generated content and the rapid spread of unverified and fake news. Denying such discourse or erasing digital traces is therefore futile. Developing a critical approach to information is essential for consistently identifying fake news, doctored images, and recordings taken out of context, as well as preventing their spread. Full article
Show Figures

Figure 1

Figure 1
<p>Graphic representation of triangular fuzzy numbers.</p>
Full article ">Figure 2
<p>Graphic representation of decision-making.</p>
Full article ">Figure 3
<p>The weights of the core skills subcriteria X1.</p>
Full article ">Figure 4
<p>Graphical representation of final weights of most influential core skills and soft skills subcriteria obtained using the AHP and FAHP method with different degrees of optimism.</p>
Full article ">Figure 5
<p>The most influential subcriteria singled out for AHP and FAHP.</p>
Full article ">Figure 6
<p>Ranking similarity.</p>
Full article ">Scheme 1
<p>Conceptual model.</p>
Full article ">
21 pages, 6529 KiB  
Article
Radial Data Visualization-Based Step-by-Step Eliminative Algorithm to Predict Colorectal Cancer Patients’ Response to FOLFOX Therapy
by Jakub Kryczka, Rafał Adam Bachorz, Jolanta Kryczka and Joanna Boncela
Int. J. Mol. Sci. 2024, 25(22), 12149; https://doi.org/10.3390/ijms252212149 - 12 Nov 2024
Viewed by 1014
Abstract
Application of the FOLFOX scheme to colorectal cancer (CRC) patients often results in the development of chemo-resistance, leading to therapy failure. This study aimed to develop a functional and easy-to-use algorithm to predict patients’ response to FOLFOX treatment. Transcriptomic data of CRC patient’s [...] Read more.
Application of the FOLFOX scheme to colorectal cancer (CRC) patients often results in the development of chemo-resistance, leading to therapy failure. This study aimed to develop a functional and easy-to-use algorithm to predict patients’ response to FOLFOX treatment. Transcriptomic data of CRC patient’s samples treated with FOLFOX were downloaded from the Gene Expression Omnibus database (GSE83129, GSE28702, GSE69657, GSE19860 and GSE41568). Comparing the expression of top up- and downregulated genes in FOLFOX responder and non-responder patients’ groups, we selected 30 potential markers that were used to create a step-by-step eliminative procedure based on modified radial data visualization, which depicts the interplay between the expression level of chosen attributes (genes) to locate data points in low-dimensional space. Our analysis proved that FOLFOX-resistant CRC samples are predominantly characterized by upregulated expression levels of TMEM182 and MCM9 and downregulated LRRFIP1. Additionally, the procedure developed based on expression levels of TMEM182, MCM9, LRRFIP1, LAMP1, FAM161A, KLHL36, ETV5, RNF168, SRSF11, NCKAP5, CRTAP, VAMP2, ZBTB49 and RIMBP2 proved to be capable in predicting FOLFOX therapy response. In conclusion, our approach can give a unique insight into clinical decision-making regarding therapy scheme administration, potentially increasing patients’ survival and, consequently, medical futility due to incorrect therapy application. Full article
Show Figures

Figure 1

Figure 1
<p>Differently expressed gene (DEG) distribution and selection using GEO GSE83129, GSE28702, and GSE69657 datasets. DEG distribution was analyzed using GEO2R and visualized by Volcano and Mean-difference plots. Data sets’ random probability distribution was analyzed by moderate t-stochastic plots. Commonly dysregulated genes for all 3 data sets were selected using Venn diagram and visualized by FunRich software (v3.1.3).</p>
Full article ">Figure 2
<p>Comparative analysis of FOLFOX resistance-related upregulated gene functional enrichment. Percentage share of genes enriched in Biological process (Bp) were calculated and visualized using FunRich software (v3.1.3) supported by Gene Ontology (GO) database.</p>
Full article ">Figure 3
<p>Comparative analysis of FOLFOX resistance-related downregulated genes’ functional enrichment. The percentage of genes enriched in Biological process (Bp) were calculated and visualized using FunRich software (v3.1.3) supported by the Gene Ontology (GO) database.</p>
Full article ">Figure 4
<p>FOLFOX response discriminating abilities of <span class="html-italic">TMEM182</span>, MCM9, and <span class="html-italic">LRRFIP1</span> gene expression level. Visualization was performed using Orange data mining and linear projections. The Red dashed line triangle depicts predicted FOLFOX-sensitive instances of respective datasets, blue dashed line triangle depicts predicted FOLFOX-resistant instances. The actual FOLFOX response in samples from GSE83129, GSE28702, GSE69657, and GSE41568 datasets is presented as a red and blue color of depicted points. The GSE41568 data set presents predicted FOLFOX response of primary CRC, lung, liver, and omentum metastasis.</p>
Full article ">Figure 5
<p>Visual depiction of FOLFOX resistance up- and downregulated genes that can be utilized as predictive features. Visualization was performed using FunRich software (v3.1.3).</p>
Full article ">Figure 6
<p>FOLFOX resistance marker characteristics. Hierarchical clustering analysis of chosen DEGs was analyzed and visualized using Orange data mining software for each data set. The percentage share of up- and downregulated genes functionally enriched in Biological process (Bp), and Molecular functions (Mf) were calculated and visualized using FunRich software (v3.1.3) supported by the Gene Ontology (GO) database.</p>
Full article ">Figure 7
<p>Step-by-step FOLFOX response predictive algorithm. (<b>A</b>) The block scheme of the step-by-step algorithm workflow. The first ① step uses the Cartesian coordinate system and expression level of <span class="html-italic">TMEM182</span>, <span class="html-italic">MCM9</span>, <span class="html-italic">LRRFIP1</span>, and <span class="html-italic">LAMP1</span> to eliminate only sensitive samples that are located in <span class="html-italic">LAMP1</span> and <span class="html-italic">LRRFIP1</span> quarter. Second strep ② uses <span class="html-italic">FAM161A</span>, <span class="html-italic">KLHL36</span>, and <span class="html-italic">ETV5</span> genes to eliminate resistant samples (located in the <span class="html-italic">FAM161A</span> and <span class="html-italic">ETV5</span> arm). The third step ③ again eliminates sensitive samples using <span class="html-italic">RNF168</span>, <span class="html-italic">SRSF11</span>, <span class="html-italic">NCKAP5</span>, and <span class="html-italic">CRTAP</span>, located in <span class="html-italic">CRTAP</span> and <span class="html-italic">RNF168</span> quarter. The final-forth step ④, with lower accuracy, separates sensitive, resistant, and mixed (hard to interpret) samples using <span class="html-italic">VAMP2</span>, <span class="html-italic">ZBTB49</span>, and <span class="html-italic">RIMBP2</span>. Sensitive samples are located on the <span class="html-italic">VAMP2</span> and <span class="html-italic">RIMBP2</span> arm, whereas resistant samples are on <span class="html-italic">RIMBP2</span> and <span class="html-italic">ZBTB49</span>. Lower panels present algorithm workflow using training sets GSE83129 and GSE28702 (<b>B</b>) and algorithms test group GSE69657 (<b>C</b>) with every step depicted as in (<b>A</b>). Visualization was performed using Orange data mining and linear projections. The dashed line depicts excluded clusters of homogenous response (red-sensitive, blue-resistant).</p>
Full article ">Figure 8
<p>FOLFOX response discriminating abilities of the proposed step-by-step algorithm, based on the expression level of chosen DEGs using the GSE19860 (<b>A</b>) and GSE41568 (<b>B</b>) GEO datasets. Visualization was performed using Orange data mining and linear projections. The dashed line depicts excluded clusters of homogenous response (red-sensitive, blue-resistant). Each step is depicted according to <a href="#ijms-25-12149-f007" class="html-fig">Figure 7</a>A as ①–④.</p>
Full article ">
10 pages, 1102 KiB  
Review
From the INVICTUS Trial to Current Considerations: It’s Not Time to Retire Vitamin K Inhibitors Yet!
by Akshyaya Pradhan, Somya Mahalawat and Marco Alfonso Perrone
Pharmaceuticals 2024, 17(11), 1459; https://doi.org/10.3390/ph17111459 - 31 Oct 2024
Viewed by 1691
Abstract
Atrial fibrillation (AF) is a common arrhythmia in clinical practice, and oral anticoagulation is the cornerstone of stroke prevention in AF. Direct oral anticoagulants (DOAC) significantly reduce the incidence of intracerebral hemorrhage with preserved efficacy for preventing stroke compared to vitamin K antagonists [...] Read more.
Atrial fibrillation (AF) is a common arrhythmia in clinical practice, and oral anticoagulation is the cornerstone of stroke prevention in AF. Direct oral anticoagulants (DOAC) significantly reduce the incidence of intracerebral hemorrhage with preserved efficacy for preventing stroke compared to vitamin K antagonists (VKA). However, the pivotal randomized controlled trials (RCTs) of DOAC excluded patients with valvular heart disease, especially mitral stenosis, which remains an exclusion criterion for DOAC use. The INVICTUS study was a large multicenter global RCT aimed at evaluating the role of DOAC compared to VKA in stroke prevention among patients with rheumatic valvular AF. In this study, rivaroxaban failed to prove superiority over VKA in preventing the composite primary efficacy endpoints of stroke, systemic embolism, myocardial infarction, and death. Unfortunately, the bleeding rates were not lower with rivaroxaban either. The death and drug discontinuation rates were higher in the DOAC arm. Close to the heels of the dismal results of INVICTUS, an apixaban trial in prosthetic heart valves, PROACT-Xa, was also prematurely terminated due to futility. Hence, for AF complicating moderate-to-severe mitral stenosis or prosthetic valve VKA remains the standard of care. However, DOAC can be used in patients with surgical bioprosthetic valve implantation, TAVR, and other native valve diseases with AF, except for moderate-to-severe mitral stenosis. Factor XI inhibitors represent a breakthrough in anticoagulation as they aim to dissociate thrombosis from hemostasis, thereby indicating a potential to cut down bleeding further. Multiple agents (monoclonal antibodies—e.g., osocimab, anti-sense oligonucleotides—e.g., fesomersen, and small molecule inhibitors—e.g., milvexian) have garnered positive data from phase II studies, and many have entered the phase III studies in AF/Venous thromboembolism. Future studies on conventional DOAC and new-generation DOAC will shed further light on whether DOAC can dethrone VKA in valvular heart disease. Full article
(This article belongs to the Special Issue Advancements in Cardiovascular and Antidiabetic Drug Therapy)
Show Figures

Figure 1

Figure 1
<p>Rates of events in the INVICTUS trial in the Rivaroxaban and VKA arms. [VKA—Vitamin K antagonist].</p>
Full article ">Figure 2
<p>Current evidence-based approach to choice of oral anticoagulation in patients with AF with underlying VHD. The left panel depicts the subset of VHD, while the middle panel suggests the appropriate oral anticoagulant—DOAC/VKA. The right panel displays the evidence base for recommendation of oral anticoagulant in each scenario. [VHD, valvular heart disease; TAVR—transcatheter aortic valve replacement; MS—mitral stenosis; DOAC, direct oral anticoagulant; VKA—Vitamin K antagonist].</p>
Full article ">Figure 3
<p>Current clinical scenario’s in AF patients where VKA’s would be still the first line agent for OAC. The upper right panel depicts a St. Jude’s bi-leaflet prosthetic valve. The lower right panel depicts the 2D transthoracic echocardiogram images in patients with severe rheumatic mitral stenosis. The lower left picture represents the triad of antiphospholipid antibody syndrome—recurrent abortions, arterial (red)/venous (blue) thrombosis, and a positive ELISA test for anti-cardiolipin/anti-B<sub>2</sub>-microglobulin antibody. [VKA—Vitamin K antagonist; DOAC—direct-acting anticoagulant; ELISA—enzyme-linked immunosorbent assay].</p>
Full article ">
19 pages, 5197 KiB  
Article
Fermented Soymilk with Probiotic Lactobacilli and Bifidobacterium Strains Ameliorates Dextran-Sulfate-Sodium-Induced Colitis in Rats
by Ashwag Jaman Al Zahrani, Amal Bakr Shori and Effat Al-Judaibi
Nutrients 2024, 16(20), 3478; https://doi.org/10.3390/nu16203478 - 14 Oct 2024
Cited by 2 | Viewed by 2323
Abstract
Background: Current treatments for inflammatory bowel disease (IBD) are relatively futile and the extended use of drugs may reduce effectiveness. Several probiotic strains have shown promise in relieving/treating IBD symptoms. Objectives: The current study investigated the impact of fermented soymilk with [...] Read more.
Background: Current treatments for inflammatory bowel disease (IBD) are relatively futile and the extended use of drugs may reduce effectiveness. Several probiotic strains have shown promise in relieving/treating IBD symptoms. Objectives: The current study investigated the impact of fermented soymilk with a mixture of probiotic starter cultures containing Lactobacillus rhamnosus, L. casei, L. plantarum, L. acidophilus, Bifidobacterium longum, and B. animalis subsp. lactis in rats with dextran sulfate sodium (DSS)-induced colitis compared to control. Methods: Rats were randomly assigned to five groups (5 rats/group; n = 25): G1: negative normal control; G2: positive control (DSS); G3: DSS with sulfasalazine (DSS-Z); G4: DSS with soymilk (DSS-SM), and G5: DSS with fermented soymilk (DSS-FSM). Parameters monitored included the following: the disease activity index (DAI), macroscopic and histological assessments of colitis, and a fecal microbial analysis performed to assess the severity of inflammation and ulceration. Results: The DSS-FSM rats group exhibited lower DAI scores (p < 0.05) than other treated groups during the induction period. A macroscopical examination revealed no ulceration or swelling in the intestinal mucosa of rats in the DSS-FSM-treated group, resembling the findings in the negative control group. In the positive control (DSS group), the colon tissue showed increased inflammation (p < 0.05), whereas those in the DSS-SM- and DSS-FSM-treated rats groups did not show significant macroscopic scores of colitis. The positive DSS control and DSS-Z groups had crypt erosion and ulceration areas, severe crypt damage, and epithelial surface erosion, which were absent in the negative control and DSS-FSM groups. The counts of Lactobacillus spp. and Bifidobacterium spp. remained stable in both G1 and G5 over 4 weeks. The consumption of fermented soymilk with a mixture of probiotics could minimize the severity of DSS-induced colitis in rats. Conclusion, it was found that fermented soymilk containing Lactobacilli and Bifidobacterium might be an effective vehicle for reducing the severity of DSS-induced colitis in rats. Full article
(This article belongs to the Topic Advances in Animal-Derived Non-Cow Milk and Milk Products)
Show Figures

Figure 1

Figure 1
<p>Evaluation of colitis. (<b>A</b>) Disease activity index (DAI); and (<b>B</b>) body weight change (%) during the induction period in week 2. G1: normal group; G2: DSS group; G3: test groups treated with sulfasalazine; G4: test groups treated with soymilk; and G5: test groups treated with fermented soymilk. Data are presented as mean ± SEM. * The level of significance was present at <span class="html-italic">p</span> &lt; 0.05 compared to the control at the same period (5 rats/group; n = 25).</p>
Full article ">Figure 1 Cont.
<p>Evaluation of colitis. (<b>A</b>) Disease activity index (DAI); and (<b>B</b>) body weight change (%) during the induction period in week 2. G1: normal group; G2: DSS group; G3: test groups treated with sulfasalazine; G4: test groups treated with soymilk; and G5: test groups treated with fermented soymilk. Data are presented as mean ± SEM. * The level of significance was present at <span class="html-italic">p</span> &lt; 0.05 compared to the control at the same period (5 rats/group; n = 25).</p>
Full article ">Figure 2
<p>Macroscopic examination of the colons in different groups of rats. G1: normal group; G2: DSS group; G3: test groups treated with sulfasalazine; G4: test groups treated with soymilk; and G5: test groups treated with fermented soymilk.</p>
Full article ">Figure 3
<p>Macroscopic analysis of damage along the colon, which includes macroscopic score (<b>A</b>), colon length (<b>B</b>), and colon weight/length (<b>C</b>). G1: normal group; G2: DSS group; G3: test groups treated with sulfasalazine; G4: test groups treated with soymilk; and G5: test groups treated with fermented soymilk. Data are presented as mean ± SEM. The significance level was present at <span class="html-italic">p</span> &lt; 0.05 compared to the control at the same period (5 rats/group; n = 25). <sup>abcde</sup> means with different superscript letters indicate the significance level at <span class="html-italic">p</span> &lt; 0.05 compared to control.</p>
Full article ">Figure 4
<p>Representative photomicrographs from the different experimental colon groups, stained with hematoxylin/eosin. G1: negative control—healthy epithelium, G2: positive control—crypt erosion (the arrow exhibited epithelium with severe crypt damage), G3: DSS with sulfasalazine—ulceration area (the arrows exhibited epithelium with severe crypt damage), and G4 and G5: DSS with soymilk and DSS with fermented soymilk, respectively—inflammatory cell infiltrated areas, with no crypt alteration.</p>
Full article ">Figure 5
<p>Viable cell counts (VCCs) of <span class="html-italic">Lactobacillus</span> spp. (<b>A</b>) and <span class="html-italic">Bifidobacterium</span> spp. (<b>B</b>) among the groups. G1: normal group; G2: DSS group; G3: test groups treated with sulfasalazine; G4: test groups treated with soymilk; and G5: test groups treated with fermented soymilk. Data are presented as mean ± SEM. The significance level was present at <span class="html-italic">p</span> &lt; 0.05 compared to the control at the same period (5 rats/group; n = 25). <sup>abc</sup> means with different superscript letters indicate the significance level at <span class="html-italic">p</span> &lt; 0.05 compared to control.</p>
Full article ">
17 pages, 765 KiB  
Review
Management of Acute Coronary Syndrome in Elderly Patients: A Narrative Review through Decisional Crossroads
by Roberto Verardi, Gianmarco Iannopollo, Giulia Casolari, Giampiero Nobile, Alessandro Capecchi, Matteo Bruno, Valerio Lanzilotti and Gianni Casella
J. Clin. Med. 2024, 13(20), 6034; https://doi.org/10.3390/jcm13206034 - 10 Oct 2024
Viewed by 2151
Abstract
Diagnosis and treatment of acute coronary syndrome (ACS) pose particular challenges in elderly patients. When high troponin levels are detected, the distinction between non-ischemic myocardial injury (NIMI), type 1, and type 2 myocardial infarction (MI) is the necessary first step to guide further [...] Read more.
Diagnosis and treatment of acute coronary syndrome (ACS) pose particular challenges in elderly patients. When high troponin levels are detected, the distinction between non-ischemic myocardial injury (NIMI), type 1, and type 2 myocardial infarction (MI) is the necessary first step to guide further care. However, the assessment of signs of ischemia is hindered in older patients, and no simple clinical or laboratory tool proved useful in this discrimination task. Current evidence suggests a benefit of an invasive vs. conservative approach in terms of recurrence of MI, with no significant impact on mortality. In patients with multivessel disease in which the culprit lesion has been treated, a physiology-guided complete percutaneous revascularization significantly reduced major events. The management of ACS in elderly patients is an example of the actual need for a multimodal, thorough clinical approach, coupled with shared decision-making, in order to ensure the best treatment and avoid futility. Such a need will likely grow throughout the next decades, with the aging of the world population. In this narrative review, we address pivotal yet common questions arising in clinical practice while caring for elderly patients with ACS. Full article
(This article belongs to the Special Issue Advancements in Myocardial Infarction Care: Strategies and Outcomes)
Show Figures

Figure 1

Figure 1
<p>Predisposing and precipitating factors of type 2 myocardial infarction.</p>
Full article ">Figure 2
<p>Diagnostic approach to elderly patients with suspected ACS. ACS = acute coronary syndrome; URL = upper reference limit; ECG = electrocardiogram; CMR = cardiac magnetic resonance; CCTA = coronary computed tomography angiography; MI = myocardial infarction; NIMI = non-ischemic myocardial injury; Hb = hemoglobin; BNP = brain natriuretic peptide; CRP = C reactive protein.</p>
Full article ">
17 pages, 2609 KiB  
Article
Assessment of Antibiotic Resistance in Pediatric Infections: A Romanian Case Study on Pathogen Prevalence and Effective Treatments
by Maria Madalina Singer, Renata Maria Văruț, Cristina Popescu, Kristina Radivojevic, Luciana Teodora Rotaru, Damian Roni Octavian, Banicioiu Mihai-Covei, Mihaela Popescu, Oancea Andreea Irina, Dragos Oancea, Alin Iulian Silviu Popescu and Cristina Elena Singer
Antibiotics 2024, 13(9), 879; https://doi.org/10.3390/antibiotics13090879 - 13 Sep 2024
Viewed by 1329
Abstract
Antibiotic misuse in Romania has exacerbated the issue of antibiotic resistance, as patients often use antibiotics without proper medical consultation. This study aimed to assess the resistance of prevalent bacteria to different antibiotics. In this observational study conducted over six months, we analyzed [...] Read more.
Antibiotic misuse in Romania has exacerbated the issue of antibiotic resistance, as patients often use antibiotics without proper medical consultation. This study aimed to assess the resistance of prevalent bacteria to different antibiotics. In this observational study conducted over six months, we analyzed 31 pediatric patients aged from 12 days to 13 years using the disk diffusion method. We identified 31 bacterial isolates, including 8 Gram-negative and 8 Gram-positive strains, with the most common being Pseudomonas aeruginosa, Escherichia coli, Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus, Streptococcus species, and Elizabethkingia meningoseptica. Our findings revealed that the most effective antibiotics were linezolid, ertapenem, and teicoplanin. In contrast, nearly all tested bacteria exhibited resistance to penicillin, followed by oxacillin and ampicillin. Resistance to cephalosporins varied with generation, showing higher resistance to lower-generation cephalosporins. The study highlights significant antibiotic resistance among common bacterial pathogens in Romanian pediatric patients, emphasizing the urgent need for controlled antibiotic use and alternative treatment strategies to combat this growing issue. Effective antibiotics such as linezolid and ertapenem offer potential solutions, whereas reliance on penicillin and lower-generation cephalosporins is increasingly futile. Full article
Show Figures

Figure 1

Figure 1
<p>Frequency distribution of pediatric conditions by number of appearances.</p>
Full article ">Figure 2
<p>Percentages of different bacterial pathogens identified in the study population, representing the global proportion of each bacterial type across all pathologies. Bacterial species have been highlighted with distinct colors (<span class="html-italic">Staphylococcus</span> species: gray; <span class="html-italic">Acinetobacter</span> species: green; <span class="html-italic">Streptococcus</span> species: orange).</p>
Full article ">Figure 3
<p>(<b>A</b>) Percentages of different pathologies diagnosed in our patients. (<b>B</b>) Age distribution of pathologies in pediatric patients.</p>
Full article ">Figure 3 Cont.
<p>(<b>A</b>) Percentages of different pathologies diagnosed in our patients. (<b>B</b>) Age distribution of pathologies in pediatric patients.</p>
Full article ">Figure 4
<p>Global antibiotic activity against bacterial pathogens in pediatric patients.</p>
Full article ">
11 pages, 775 KiB  
Article
Withdrawal/Withholding of Life-Sustaining Therapies: Limitation of Therapeutic Effort in the Intensive Care Unit
by Ángel Becerra-Bolaños, Daniela F. Ramos-Ahumada, Lorena Herrera-Rodríguez, Lucía Valencia-Sola, Nazario Ojeda-Betancor and Aurelio Rodríguez-Pérez
Medicina 2024, 60(9), 1461; https://doi.org/10.3390/medicina60091461 - 6 Sep 2024
Viewed by 1106
Abstract
Background/Objectives: The change in critically ill patients makes limitation of therapeutic effort (LTE) a widespread practice when therapeutic goals cannot be achieved. We aimed to describe the application of LTE in a post-surgical Intensive Care Unit (ICU), analyze the measures used, the [...] Read more.
Background/Objectives: The change in critically ill patients makes limitation of therapeutic effort (LTE) a widespread practice when therapeutic goals cannot be achieved. We aimed to describe the application of LTE in a post-surgical Intensive Care Unit (ICU), analyze the measures used, the characteristics of the patients, and their evolution. Methods: Retrospective observational study, including all patients to whom LTE was applied in a postsurgical ICU between January 2021 and December 2022. The LTE defined were brain death, withdrawal of measures, and withholding. Withholding limitations included orders for no cardiopulmonary resuscitation, no orotracheal intubation, no reintubation, no tracheostomy, no renal replacement therapies, and no vasoactive support. Patient and ICU admission data were related to the applied LTE. Results: Of the 2056 admitted, LTE protocols were applied to 106 patients. The prevalence of LTE in the ICU was 5.1%. Data were analyzed in 80 patients. A total of 91.2% of patients had been admitted in an emergency situation, and 56.2% had been admitted after surgery. The most widespread limitation was treatment withholding (83.8%) compared to withdrawal (13.8%). No differences were found regarding who made the decision and the type of limitation employed. However, patients with the limitation of no intubation had a longer stay (p = 0.025). Additionally, the order of not starting or increasing vasopressor support resulted in a longer hospital stay (p = 0.007) and a significantly longer stay until death (p = 0.044). Conclusions: LTE is a frequent measure in critically ill patient management and is less common in the postoperative setting. The most widespread measure was withholding, with the do-not-resuscitate order being the most common. The decision was made mainly by the medical team and the family, respecting the wishes of the patients. A joint patient-centered approach should be made in these decisions to avoid futile treatment and ensure end-of-life comfort. Full article
(This article belongs to the Section Intensive Care/ Anesthesiology)
Show Figures

Figure 1

Figure 1
<p>Flow diagram of patients included in the analysis.</p>
Full article ">Figure 2
<p>Limitation of therapeutic effort decision proposal.</p>
Full article ">
Back to TopTop